Search for drugs:
Typing the drug name to query
EDOXABAN TOSYLATE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Cardiac Electrophysiology
- In a thorough QT study in healthy men and women aged 19-45 years, no QTc interval prolongation was observed with edoxaban (90 mg and 180 mg).
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
0
24092
Other ADRs
8636
38372951
Odds Ratio = 0.0
Drug Property Information
ATC Code(s):
- B01AF03 - edoxaban tosylate
- B01AF -
- B01A - ANTITHROMBOTIC AGENTS
- B01 - ANTITHROMBOTIC AGENTS
- B - BLOOD AND BLOOD FORMING ORGANS
Active Ingredient:EDOXABAN TOSYLATE
Active Ingredient UNII:32W99UE810
Drugbank ID:DB09075
PubChem Compound:10280735
CTD ID:C552171
PharmGKB:PA166128806
CAS Number:480449-70-5
Dosage Form(s):tablet, film coated
Route(s) Of Administrator:oral
Daily Dose:
- 60.0 mg/day B01AF03
Chemical Structure: 
SMILE Code:
CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
CN(C)C(=O)[C@H]1CC[C@H](NC(=O)C(=O)NC2=NC=C(Cl)C=C2)[C@@H](C1)NC(=O)C1=NC2=C(CN(C)CC2)S1
Reference
N/A
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.